ASA, NSAIDs, Coxibs and Colorectal Cancer Prevention — How Far Have We Come?
This paper described a nested case-control study on all Quebec patients over 65 years of age who underwent total colonic imaging or surgery for colorectal cancer (CRC) during a specified six-month period without similar testing in the preceding year. Information from the provincial government da...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2004-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2004/862152 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567037883318272 |
|---|---|
| author | Martin Fishman |
| author_facet | Martin Fishman |
| author_sort | Martin Fishman |
| collection | DOAJ |
| description | This paper described a nested case-control study on all Quebec patients over 65 years of age who underwent total colonic imaging or surgery for colorectal cancer (CRC) during a specified six-month period without similar testing in the preceding year. Information from the provincial government database was collected for each subject to estimate the consumption of prescription acetylsalicylic acid (ASA), standard nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2- specific inhibitors (coxibs) during the previous year. Of 2568 subjects, 730 were found to have at least one adenoma (but not carcinoma) and 129 were found to have CRC (with or without adenoma). Patients with and without adenoma or carcinoma were compared for type, amount and duration of drug exposure to determine if there was a protective effect. Rofecoxib and NSAIDs were associated with reduced incidence of colorectal adenoma (CRA), and these drugs and celecoxib protected against CRA and CRC. |
| format | Article |
| id | doaj-art-6989567a1f5c4a26b6176ded715bf72a |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2004-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-6989567a1f5c4a26b6176ded715bf72a2025-02-03T01:02:32ZengWileyCanadian Journal of Gastroenterology0835-79002004-01-0118746746810.1155/2004/862152ASA, NSAIDs, Coxibs and Colorectal Cancer Prevention — How Far Have We Come?Martin FishmanThis paper described a nested case-control study on all Quebec patients over 65 years of age who underwent total colonic imaging or surgery for colorectal cancer (CRC) during a specified six-month period without similar testing in the preceding year. Information from the provincial government database was collected for each subject to estimate the consumption of prescription acetylsalicylic acid (ASA), standard nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2- specific inhibitors (coxibs) during the previous year. Of 2568 subjects, 730 were found to have at least one adenoma (but not carcinoma) and 129 were found to have CRC (with or without adenoma). Patients with and without adenoma or carcinoma were compared for type, amount and duration of drug exposure to determine if there was a protective effect. Rofecoxib and NSAIDs were associated with reduced incidence of colorectal adenoma (CRA), and these drugs and celecoxib protected against CRA and CRC.http://dx.doi.org/10.1155/2004/862152 |
| spellingShingle | Martin Fishman ASA, NSAIDs, Coxibs and Colorectal Cancer Prevention — How Far Have We Come? Canadian Journal of Gastroenterology |
| title | ASA, NSAIDs, Coxibs and Colorectal Cancer Prevention — How Far Have We Come? |
| title_full | ASA, NSAIDs, Coxibs and Colorectal Cancer Prevention — How Far Have We Come? |
| title_fullStr | ASA, NSAIDs, Coxibs and Colorectal Cancer Prevention — How Far Have We Come? |
| title_full_unstemmed | ASA, NSAIDs, Coxibs and Colorectal Cancer Prevention — How Far Have We Come? |
| title_short | ASA, NSAIDs, Coxibs and Colorectal Cancer Prevention — How Far Have We Come? |
| title_sort | asa nsaids coxibs and colorectal cancer prevention how far have we come |
| url | http://dx.doi.org/10.1155/2004/862152 |
| work_keys_str_mv | AT martinfishman asansaidscoxibsandcolorectalcancerpreventionhowfarhavewecome |